MXCT
Company Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.03M | 38.63M | 41.29M | 44.26M | 33.89M | 26.17M | 21.62M | 16.67M | 13.98M | 12.27M | 9.29M | 7.16M |
| Net Income | (44.63M) | (41.05M) | (37.92M) | (23.57M) | (19.08M) | (11.82M) | (12.89M) | (8.87M) | (9.92M) | (3.35M) | (1.45M) | (1.84M) |
| EPS | -0.42 | -0.39 | -0.37 | -0.19 | -0.22 | -0.18 | -0.24 | -0.17 | -0.20 | -0.10 | -0.03 | -1.59 |
| Free Cash Flow | (36.18M) | (29.26M) | (25.39M) | (33.26M) | (14.51M) | (10.85M) | (10.07M) | (11.20M) | (10.29M) | (2.55M) | N/A | N/A |
| FCF / Share | -0.34 | -0.28 | -0.25 | -0.33 | -0.16 | -0.16 | -0.18 | -0.22 | -0.21 | -0.08 | N/A | N/A |
| Operating CF | (34.41M) | (27.61M) | (21.69M) | (14.78M) | (10.68M) | (8.78M) | (8.80M) | (10.49M) | (9.68M) | (2.33M) | N/A | N/A |
| Total Assets | 202.51M | 239.47M | 268.27M | 286.65M | 284.12M | 51.78M | 29.99M | 24.27M | 31.40M | 16.07M | N/A | N/A |
| Total Debt | 17.94M | 18.03M | 18.74M | 16.09M | 5.68M | 6.97M | 7.21M | 5.06M | 5.03M | 5.01M | N/A | N/A |
| Cash & Equiv | 20.07M | 27.88M | 46.51M | 11.06M | 47.78M | 18.76M | 15.21M | 11.25M | 25.34M | 11.73M | N/A | N/A |
| Book Value | 171.49M | 206.25M | 232.17M | 253.97M | 262.90M | 33.23M | 13.60M | 12.28M | 19.60M | 5.08M | N/A | N/A |
| Return on Equity | -0.26 | -0.20 | -0.16 | -0.09 | -0.07 | -0.36 | -0.95 | -0.72 | -0.51 | -0.66 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.65M | 7.30M | 6.83M | 8.51M | 10.39M | 8.69M | 8.16M | 10.43M | 11.34M | 15.66M | 8.00M | 9.04M |
| Net Income | (4.75M) | (9.60M) | (12.42M) | (12.36M) | (10.26M) | (10.60M) | (11.56M) | (9.38M) | (9.53M) | (5.28M) | (11.25M) | (10.51M) |
| EPS | -0.04 | -0.09 | -0.12 | -0.12 | -0.10 | -0.10 | -0.11 | -0.09 | -0.09 | -0.05 | -0.11 | -0.10 |
| Free Cash Flow | (8.39M) | (2.92M) | (7.76M) | (10.44M) | (15.06M) | (7.97M) | (4.80M) | (5.13M) | (11.37M) | 66,900 | (8.96M) | (10.61M) |
| FCF / Share | -0.08 | -0.03 | -0.07 | -0.10 | -0.14 | -0.08 | -0.05 | -0.05 | -0.11 | 0.00 | -0.09 | -0.10 |
| Operating CF | (8.17M) | (2.69M) | (7.46M) | (9.85M) | (14.41M) | (7.82M) | (4.39M) | (4.83M) | (10.56M) | 981,700 | (8.24M) | (10.10M) |
| Total Assets | 194.47M | 202.51M | 213.48M | 219.75M | 229.96M | 239.47M | 248.61M | 251.50M | 257.93M | 268.27M | 266.73M | 271.20M |
| Total Debt | 17.49M | 17.94M | 18.16M | 18.51M | 18.82M | 18.03M | 18.32M | 18.53M | 18.64M | 18.74M | 16.08M | 16.21M |
| Cash & Equiv | 14.56M | 20.07M | 12.97M | 15.22M | 23.39M | 27.88M | 36.96M | 37.51M | 22.25M | 46.51M | 49.17M | 54.56M |
| Book Value | 167.89M | 171.49M | 180.28M | 190.72M | 199.41M | 206.25M | 213.30M | 221.26M | 226.36M | 232.17M | 233.38M | 240.98M |
| Return on Equity | -0.03 | -0.06 | -0.07 | -0.06 | -0.05 | -0.05 | -0.05 | -0.04 | -0.04 | -0.02 | -0.05 | -0.04 |
